We are on a mission to translate life sciences breakthroughs into health impact
Investment Stage: Series A
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 24.07.2025 | Respiree | respiree.com | $11.6M | Singapore |
Mentions in press and media 17
| Date | Title | Description |
| 18.10.2025 | Leyden Labs Secures €30M for Groundbreaking Respiratory Nasal Spray | Leyden Laboratories, a Dutch biotechnology pioneer, recently secured a significant €30 million in equity funding. The European Innovation Council (EIC) Fund and Invest-NL spearheaded this investment. This crucial capital injection will prop... |
| 17.10.2025 | Leyden Labs: €30 Million Secured From EIC And Invest-NL | Dutch biotechnology company Leyden Laboratories B.V. has secured €30 million in new equity financing from the European Innovation Council (EIC) Fund and Invest-NL. The investment will accelerate the clinical development of the company’s pan... |
| 02.10.2025 | Cirrus Therapeutics Raises $11M in Seed Financing | Cirrus Therapeutics, a Cambridge, MA-based ocular immunology-focused biotech company, closed an $11m seed financing. The round was led by ClavystBio, with participation from Polaris Partners and SEEDS. The company will use the financing to ... |
| 21.08.2025 | SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM | Now in its fourth year, the programme continues to empower biotech startups through ecosystem support and collaboration to advance science that serves patients. SINGAPORE, Aug. 21, 2025 /PRNewswire/ -- Singzyme, a Singapore-based biotech st... |
| 24.07.2025 | Deals in brief: Respiree raises Series A funding, HeyMax expands with Krip acquisition, latest China deals, and more | Respiree raises Series A funding to scale health monitoring AI Respiree, a health tech company founded in Singapore, has raised USD 11.6 million in a Series A funding round co-led by We Venture Capital and ClavystBio. Other participants inc... |
| 24.07.2025 | ClavystBio co-anchors $11.6m funding in healthtech Respiree | - |
| 10.06.2025 | ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore | SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and Research (A*STAR), Singapore's lead public sector R&D agency, have sign... |
| 28.05.2025 | To develop novel therapies for cardiomyopathy, Nuevocor raised $45 M Series B funding | The Singapore-based IND-stage biotechnology startup Nuevocor, which is working to find treatments for cardiomyopathies caused by aberrant mechanobiology, has successfully closed a $45 million Series B funding round. Nuevocor said in a state... |
| 07.05.2025 | Nuevocor's $45 Million Leap: A New Dawn for Cardiomyopathy Treatment | In the world of biotechnology, every dollar counts. A recent infusion of $45 million into Nuevocor, a Singapore-based company, is more than just a financial boost. It’s a lifeline for patients grappling with cardiomyopathies, particularly t... |
| 06.05.2025 | Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy | – Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund – Proceeds will support the Phase 1/2 clinical trial of le... |
Show more